Table 4 Comparison of baseline characteristics of patients with and without refracture during follow-up.

From: Long-term persistence of treatment after hip fracture in a fracture liaison service

 

No refracture (N = 320)

Refracture (N = 52)

P-value

Age (years) mean (SD), range

79.8 (8.7)

77.9 (10.0)

0.1659

Sex (female), n (%)

239 (74.7)

44 (84.6)

0.12

Type of fracture, n (%)

Pertrochanteric

169 (52.8)

22 (42.3)

0.577

Intracapsular

126 (39.4)

25 (48.1)

Subtrochanteric

20 (6.3)

4 (7.7)

Others

5 (1.6)

1 (1.9)

Identification of patients, n (%)

Emergency registry

184 (57.5)

33 (63.5)

0.383

Admission

115 (35.9)

14 (26.9)

Rheumatology osteoporosis clinic

21 (6.6)

5 (9.6)

Previous treatment with bisphosphonates, n (%)a

45 (14.2)

8 (15.7)

0.778

Risk factors for fracture, n (%)

Previous fragility fracture

63 (19.7)

14 (26.9)

0.232

Parental hip fracture

29 (9.1)

6 (11.5)

0.576

Smoking

29 (9.1)

8 (15.4)

0.158

Corticosteroids

35 (11.0)

5 (9.6)

0.77

Rheumatoid arthritis

9 (2.8)

1 (2.0)

0.723

Secondary osteoporosis

49 (15.3)

11 (21.2)

0.288

Alcohol

14 (4.4)

3 (5.8)

0.655

Densitometry results, n (%)a

Normal

10 (5.8)

2 (5.9)

0.879

Osteopenia

69 (39.9)

12 (35.3)

Osteoporosis

94 (54.3)

20 (58.8)

T score lumbar spine, mean (SD)

− 1.8 (1.6)

− 2.4 (1.6)

0.073

T score femoral neck, mean (SD)

− 2.4 (1.1)

− 2.8 (1.0)

0.088

FRAX®

FRAX® major, mean (SD)

18.2 (10.1)

19.8 (10.9)

0.304

FRAX® hip, mean (SD)

9.6 (8.1)

10.9 (9.5)

0.284

Referral after baseline visit, n (%)a

Rheumatology osteoporosis clinic

50 (15.6)

7 (13.5)

0.688

Primary care

270 (84.4)

45 (86.5)

 
  1. aPrevious treatment recorded in 369 patients. Densitometry values were recorded in 207 patients.